Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Dec 12, 2023 11:10am
94 Views
Post# 35779934

RE:RE:2023

RE:RE:2023I rule out going bust for a few reasons.  The biggest reason is Jamie and Andrew own 27,500,000 shares and for that reason alone they will do whatever it takes to extract something from their investment.

 Which leads me to the "deal". With that mountain of shares there is no way they will ever be able to sell them on the open market...it would take forever.  The only way they can move that many shares is in the sale of the company.  Who is interested ?   I think a company like Pfizer is a likely candidate.  Firstly they are flush with cash following their vaccination successes (Covid & RSV) and Replicel has valuable assets and patents that could be purchased for a small price.

I would like to think the Dermal Injector is ready for FDA Approval submission but I don't think they have secured a manufacturer for the device at this point.

<< Previous
Bullboard Posts
Next >>